兔肺VX2鳞癌移植瘤射频消融后残存肿瘤ERCC1表达的变化

Change of ERCC1 Expression of Residual VX2 Squamous Carcinoma Cells in Rabbit Lung after Radiofrequency Ablation

背景与目的残存肿瘤是影响射频消融(radiofrequency ablation,RFA)治疗肺恶性肿瘤效果的重要因素,联合铂类药物化疗是减少残存肿瘤的重要手段之一。核苷酸切除修复交叉互补基因1(excision repair crosscomplementation group 1,ERCC1)的表达水平是影响铂类药物化疗效果的重要因素之一。RFA治疗后残存肿瘤会发生一些生物学特性变化,但有关ERCC1表达变化的研究尚无报道。本研究旨在探讨RFA治疗后兔肺内残存VX2鳞癌细胞ERCC1表达水平的变化。方法应用组织块悬液注射法建立兔VX2鳞癌肺内移植瘤模型。58只荷瘤新西兰白兔随机分为对照组(n=10)和RFA组(n=48)。在RFA治疗时,通过控制电极展开范围、输出功率、治疗时间的方法,造成肿瘤残存。应用免疫组织化学方法检测残存肿瘤细胞在不同时间点ERCC1表达的阳性率。结果 RFA组残存肿瘤组织ERCC1表达阳性率在1 d-5 d呈一过性升高(53.7%±1.6%&32.9%±2.5%),5 d后恢复至对照组水平。结论因在RFA治疗后1 d-5 d内残存肿瘤细胞ERCC1表达增高,在此期间给予铂类药物化疗可能效果不佳。

Background and objective Residual carcinoma cells play an important role in the result of radiofre- quency ablation （RFA） of pulmonary malignancies, and Platinum-based adjuvant chemotherapy is one of the important treat- ment regimen to reduce residual carcinoma ceils after RFA. ERCC1 （excision repair cross-complementation group 1） is an im- portant factor affecting Platinum-based chemotherapy effects. Residual carcinoma cells exhibit some changes of their features after RFA; however, there is no report about the change of their ERCC1 expression by now. This study focused on the change of ERCC1 expression in residual VX2 squamous carcinoma cells in rabbit lung after RFA. Methods The model ofVX2 squa- mous carcinoma in rabbit lung was established by injection of tissue block suspension. Fifty-eight New Zealand White rabbits with VX2 squamous carcinoma were randomly derided into the control group （n=10） and the RFA group （n=48）. During the RFA procedure in these models, residual carcinoma cells were achieved by controlling the range of electrode expanding, power output and treatment time. At different points of time, the positive rates of ERCC1 expression in residual carcinoma were detected by immunohistochemistry. Results Comparing with the control group, the positive rate of ERCC1 expression in re- sidual carcinoma in RFA group increases transiently within 1 d to S d （53.7%±1.6% ＆ 32.9%±2.5%）, and 5 d later, it decline to the level of the control group. Conclusion The ERCC1 expression of residual pulmonary carcinoma increase within 5 d after RFA. Thus platinum-based adjuvant chemotherapy may be ineffective in this period.